Blockbuster Drugs 2006

Download

to improve the quality of future issues, please send us your comments to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

The present FREE Download contains a compilation of the 114 blockbuster drugs with 2006 sales of more than US$ 1 bln each. The report has been published in the July 6, 2007 special issue of R&D Pipeline News and has 34 pages. The report provides an overview of the TOP 10 companies with the highest sales produced by their blockbuster drug portfolio, the TOP 10 best selling blockbuster drugs in 2006, the TOP 10 Blockbuster Drug Classes with the corresponding sales in 2006 and compiles all 114 individual blockbuster drugs of 2006 by company.

Top 10 Blockbuster Companies 2006

The TOP 10 companies with highest sales originating from blockbuster drugs in 2006 a each of them posting more than US$ 1 bln in sales. Cumulated sales of blockbuster drugs of the TOP 10 companies ranged from US$ 9.4 bln to US$ 28.8 bln. The number of blockbuster drug per TOP 10 company ranged from 4 to 12.

Top 10 Blockbuster Drugs 2006

The report compiles 2006 sales of the TOP 10 best selling blockbuster drugs in 2006. The number one best selling blockbuster drug posted 2006 worldwide sales of US$ 13.6 bln. Four biologics (antibodies and proteins) are among the TOP 10 blockbuster drugs.

Top 10 Blockbuster Drug Classes 2006

The report compiles 2006 sales of the 10 major classes of blockbuster drugs. The best selling class of blockbuster drugs in 2006 achieved cumulative revenues of US$ 20.4 bln. Three of the ten best selling classes of blockbuster drugs in 2006 were biologics.

Blockbuster Drugs 2006 by Company

A total of 114 different blockbuster drugs generated 2006 sales of US$ 233.7 bln of which biologics represented 23.1 of the total. A total of 30 companies with at least one blockbuster drugs (sales more than US$ 1 bln). The number of blockbuster drugs per company ranged from 1 to 12.